Anti-SARS-CoV-2 QuantiVac ELISA (IgG)

JAVASCRIPT DISABLED - This site works best with JavaScript enabled.

Anti-SARS-CoV-2 QuantiVac ELISA (IgG)

Principle: Quantitative ELISA based on recombinant S1/RBD

Automation: YES

Approvals: CE-IVD

Suitability: Supports assessment of the level of immune reaction after SARS-CoV-2 infection or vaccination

Description:

Quantitative ELISA for determination of the concentration of IgG antibodies against the S1 antigen (including RBD) of SARS-CoV-2

Key Points:

6-point calibration curve
Excellent correlation with the WHO international standard (NIBSC code: 20/136) – enabling issuing of results in standardised units
Very good agreement of results in comparison with different neutralisation tests
Validated for serum, plasma and dried capillary blood as sample material
Fully automatable

Please note : Any products described on this page are for Research Use Only and not intended for clinical diagnostic procedures unless otherwise stated.

Areas:

Clinical

Tags: